InnoCan Pharma (HAM:IP40) PEG Ratio: N/A (As of Jun. 29, 2026)


HAM:IP40 InnoCan Pharma Corp HAM:IP40
62 GF Score
Price €1.63
GF Value €9.62
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is InnoCan Pharma PEG Ratio?

PE Ratio without NRI / 5-Year EBITDA Growth Rate*

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, InnoCan Pharma's PE Ratio without NRI is 0.00. InnoCan Pharma's 5-Year EBITDA growth rate is 0.00%. Therefore, InnoCan Pharma's PEG Ratio for today is N/A.

* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


The historical rank and industry rank for InnoCan Pharma's PEG Ratio or its related term are showing as below:



HAM:IP40's PEG Ratio is not ranked *
in the Consumer Packaged Goods industry.
Industry Median: 1.32
* Ranked among companies with meaningful PEG Ratio only.

Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.


InnoCan Pharma  (HAM:IP40) PEG Ratio Explanation

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.


InnoCan Pharma PEG Ratio Related Terms


InnoCan Pharma PEG Ratio Historical Data

* Premium members only.

The historical data trend for InnoCan Pharma's PEG Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

InnoCan Pharma PEG Ratio Chart

InnoCan Pharma Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PEG Ratio
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

InnoCan Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PEG Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

HAM:IP40 vs PG, CL, KVUE: PEG Ratio Comparison

For the Household & Personal Products subindustry, InnoCan Pharma's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InnoCan Pharma PEG Ratio vs Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, InnoCan Pharma's PEG Ratio distribution charts can be found below:

* The bar in red indicates where InnoCan Pharma's PEG Ratio falls into.


HAM:IP40
62GF Score
InnoCan Pharma Corp HAM:IP40
PEG Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

InnoCan Pharma PEG Ratio Calculation

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The ratio we use is the 5-Year EBITDA growth rate.

InnoCan Pharma's PEG Ratio for today is calculated as

PEG Ratio=PE Ratio without NRI/5-Year EBITDA Growth Rate*
=/0.00
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.

Is InnoCan Pharma (HAM:IP40) Overvalued in 2026?

Based on GuruFocus' analysis, InnoCan Pharma stock appears to be undervalued. The current stock price of €1.63 is trading 83.1% below its estimated GF Value™ of €9.62. GuruFocus considers InnoCan Pharma to be Possible Value Trap.

Key valuation signals for HAM:IP40:

  • PEG Ratio: N/A
  • GF Value™: €9.62 vs. price of €1.63 (83.1% below fair value)
  • GF Score™: 62/100 with 2 warning signs

No single metric tells the full story. See the HAM:IP40 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


InnoCan Pharma Business Description

Other Exchanges INNPF:USAINNO:Canada
Address 1015, 926 - 5 Avenue SW, Calgary, AB, CAN, T2P 0N7
InnoCan Pharma Corp develops consumer wellness and pharmaceutical products. It has developed a preclinical-stage Cannabidiol-loaded Liposome injection Platform (CBD-LPT) for non-opioid pain management, and is involved in developing and marketing various self-care and CBD beauty products. Additionally, the Group offers cosmetic products such as anti-aging beauty sleeping masks, anti-puffiness eye serum, anti-aging facial serum, hair cream, etc., which are sold mainly through online marketplaces. Its operating segments are: Online sales and Other operations. The majority of its revenue is generated from the Online sales segment, which engages in the development, manufacture, and marketing of cosmetic products. Geographically, the Group generates maximum revenue from the United States.
62GF Score

Get the complete analysis for HAM:IP40

PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.63
Price
€9.62
GF Value